ab 19 September 2025 Global Research Mindray Bio-Med APT Medical: Key growth driver Initiated coverage of APT Medical, Mindray's subsidiary, with a Buy rating We initiated on APT Medical (note), a Mindray subsidiary, with a Buy rating and a PT of Rmb428. APT is a leading manufacturer of electrophysiology (EP) and vascular interventional (VI) products in China, which may have robust 14%/10% CAGRs in 2024- 30, based on Frost & Sullivan/UBS estimates. We think APT is well positioned for above- market growth, m ...

Figma, Inc. (NYSE: FIG ) is overvalued at 29x Price-To-Sales with a target price of $27.1 per share. Figma is an excellent business, offering simultaneous editing tools for the entire design team and smooth, modular software thatInvesting in high-growth opportunities across industries, employing a value investing approach that prioritizes robust business models and strategic foresight. Focusing on companies with the potential to profoundly influence the global landscape in the years aheadI primarily employ ...

Group 1 - Intel Corporation is considered a buying opportunity due to the new CEO's extensive industry experience and previous success in turning around a company [1] - The company is currently undervalued, indicating potential for growth even without significant changes [1] - The investment strategy focuses on high-growth opportunities across various industries, emphasizing robust business models and strategic foresight [1] Group 2 - The analysis employs discounted cash flow (DCF) valuation methodology while remaining adaptable to other valuation techniques [1] - Business model frameworks from prestigious institutions are utilized for in-depth analysis, ensuring a comprehensive understanding of intrinsic value and strategic positioning [1] - The focus is on long-term growth potential and risk mitigation in investment decisions [1]